| Dr Naomi Elka Malam, MD | |
|
3055 Roslyn St Unit 100, Denver, CO 80238-3324 | |
| (720) 848-0000 | |
| Not Available |
| Full Name | Dr Naomi Elka Malam |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 7 Years |
| Location | 3055 Roslyn St Unit 100, Denver, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023541786 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DR.0064714 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Colorado Hospital Authority | Aurora, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Ortho Biotech Products, L.P. has announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).
The Engineering and Physical Sciences Research Council (EPSRC) will help the UK's world-leading researchers in synthetic biology to establish platform technology in the emerging field with a new grant of almost -5 million. Platform technology is the crucial next step necessary for applications to be produced and commercialised.
The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.
Researchers are now able to study stem cells from the brains of adult mice and their neurogenesis in long-term cell cultures.
A UCSF study holds clues to why an emerging clinical trials option for heart attack patients has not been as successful as anticipated. Treatment of human hearts with bone marrow cells has led to limited to no success in improving their heart function even though a similar method has been much more effective in rodents.
› Verified 5 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Ortho Biotech Products, L.P. has announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).
The Engineering and Physical Sciences Research Council (EPSRC) will help the UK's world-leading researchers in synthetic biology to establish platform technology in the emerging field with a new grant of almost -5 million. Platform technology is the crucial next step necessary for applications to be produced and commercialised.
The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.
Researchers are now able to study stem cells from the brains of adult mice and their neurogenesis in long-term cell cultures.
A UCSF study holds clues to why an emerging clinical trials option for heart attack patients has not been as successful as anticipated. Treatment of human hearts with bone marrow cells has led to limited to no success in improving their heart function even though a similar method has been much more effective in rodents.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Naomi Elka Malam, MD 13001 E 17th Pl, University Of Colorado School Of Medicine Gme, Aurora, CO 80045-2570 Ph: (720) 553-2696 | Dr Naomi Elka Malam, MD 3055 Roslyn St Unit 100, Denver, CO 80238-3324 Ph: (720) 848-0000 |
News Archive
Ortho Biotech Products, L.P. has announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).
The Engineering and Physical Sciences Research Council (EPSRC) will help the UK's world-leading researchers in synthetic biology to establish platform technology in the emerging field with a new grant of almost -5 million. Platform technology is the crucial next step necessary for applications to be produced and commercialised.
The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.
Researchers are now able to study stem cells from the brains of adult mice and their neurogenesis in long-term cell cultures.
A UCSF study holds clues to why an emerging clinical trials option for heart attack patients has not been as successful as anticipated. Treatment of human hearts with bone marrow cells has led to limited to no success in improving their heart function even though a similar method has been much more effective in rodents.
› Verified 5 days ago
Dr. Huy C Ly, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 W 11th Ave Apt 517, Denver, CO 80204 Phone: 720-841-6706 | |
Claire Mcvay, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2130 Stout St, Denver, CO 80205 Phone: 303-293-2220 | |
Erica L Liesmaki, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4500 E 9th Ave, Ste #320, Denver, CO 80220 Phone: 303-322-0212 Fax: 303-322-0208 | |
Dr. Zachary John Anderson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 90 Madison St, Suite 504, Denver, CO 80206 Phone: 720-524-1550 Fax: 720-524-1551 | |
George W Bock, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 777 Bannock St, Mc 7782, Denver, CO 80204 Phone: 303-436-6000 | |
Kristine Elizabeth Walsh, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2803 Roslyn St, Denver, CO 80238 Phone: 303-403-6300 Fax: 303-403-6315 | |
Dr. Caroline S Guillebaud, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4720 Tejon St, Denver, CO 80211 Phone: 303-433-6563 Fax: 303-433-5614 |